Given the pivotal involvement of CASC15 in synaptic plasticity and the distinctive regulatory mechanisms of the CASC15‐FMR1‐NTF3 axis, CASC15 emerges as a promising biomarker for Alzheimer's disease and may even possess potential as a feasible therapeutic target. This evidence concerns the gene FMR1 and early-onset autosomal dominant Alzheimer disease.